Here is the situation. Employers are projecting a 10% increase in health care costs in 2026, according to the International Foundation of Employee Benefit Plans — and GLP-1 weight-loss medications are sitting at the center of that number. These drugs now account for an estimated 14% of all prescription drug spending nationally. Your employees know what Ozempic and Wegovy are. Some of them are already asking whether their plan covers it. And if you haven’t built a deliberate GLP-1 employer coverage strategy, your next renewal is going to force the conversation whether you’re ready or not.
This isn’t just a large-company problem. Mid-size employers on self-funded or level-funded plans are navigating the same pressure — and in some ways face harder tradeoffs, with less negotiating leverage and tighter stop-loss arrangements.
What’s Actually at Stake
GLP-1 drugs run approximately $400 to $700 per member per month on employer health plans. That’s before rebates — and rebate structures vary significantly depending on your pharmacy benefit manager (PBM) contract. For a plan covering 200 employees, even modest GLP-1 utilization can shift your pharmacy line item materially within a single plan year.
One PBM-reported case cited by the Program on Health Technology and Innovation found that an employer’s pharmacy spend “shot through” projected budgets by mid-June after adding broad GLP-1 coverage for weight loss. That’s not an outlier. It’s increasingly the norm for plans that add coverage without building guardrails first.
At the same time, the clinical case for these medications is real. A 2024 analysis by Aon found that GLP-1 users showed a 3% increase in medical cost growth over 18 months — versus 9% for a control group. Long-term reductions in cardiovascular claims, hospitalizations, and bariatric surgery are plausible outcomes. The math just doesn’t clear in the short window most employees are covered by any single employer’s plan.

The Three Positions Employers Are Taking
Right now, employers are clustering into three broad coverage approaches, each with real tradeoffs:
Diabetes-only coverage. This approach covers GLP-1 medications for FDA-approved type 2 diabetes treatment only and excludes obesity indications. It controls incremental cost, but it’s becoming harder to defend as clinical evidence for cardiovascular benefit expands and employee expectations shift.
Managed access with guardrails. This is where most mid-size employers finding sustainable outcomes are landing. Prior authorization, clinical eligibility criteria above the FDA label, required participation in a lifestyle or weight management program, and quantity limits combine to create coverage that’s defensible, fair, and measurable. According to Mercer, about 38% of employers with GLP-1 coverage now require lifestyle program participation as a condition of continued access.
Full exclusion. This was a common default in 2023 and 2024. In 2026, it creates increasing competitive and equity pressure — particularly in labor markets where GLP-1 access has become a visible benefits differentiator.
What to Do Before Your Next Renewal
Start by auditing what your plan is actually paying today. Many employers discover GLP-1 utilization already in their claims data — often under diabetes indications — before a formal obesity coverage policy is in place. Understanding your baseline is the prerequisite to everything else.
Engage your PBM or broker on utilization management options: prior authorization, indication-specific coverage, step therapy, and preferred drug list positioning. Review your stop-loss contract language specifically — some carriers are adding GLP-1-specific exclusions or adjusting attachment points, which creates a gap in your catastrophic cost protection that requires a plan design response.
Finally, build your employee communication now. GLP-1 drugs are heavily marketed directly to consumers. Employees will ask questions. A clear FAQ that explains what your plan covers, what it doesn’t, and why — applied consistently across all eligible employees — reduces confusion, limits informal escalations to HR, and protects you from claims of disparate treatment.
Your benefits strategy team can help you model the budget impact of different coverage approaches before you commit. Your pharmacy management strategy is equally critical — PBM contract structure and formulary positioning can meaningfully change what your plan actually spends, regardless of what your coverage policy says on paper.
The employers who are getting GLP-1 right in 2026 are not the ones with the most generous policies or the most restrictive ones. They are the ones with the most deliberately structured policies. That deliberateness starts before renewal — not during it.
Ready to build a GLP-1 coverage strategy that protects your plan without alienating your workforce? The team at Tooher-Ferraris has been helping businesses navigate complex benefits decisions since 1932. Contact us today to schedule a no-obligation consultation.





